Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: Who does not always need testing?

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 413-424

  Allison, K H ^a   Kandalaft, P L ^b   Sitlani, C M ^a   Dintzis, S M ^a   Gown, A M ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b PHENOPATH LABORATORIES   (United States)

Author keywords

21 gene recurrence score assay; Breast cancer; Estrogen receptor; Immunohistochemistry; Ki67; Nottingham grade; Oncotype DX; Progesterone receptor; Recurrence score; RT PCR

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PODOPLANIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 84856226700     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1416-3     Document Type: Article

References (27)

1. S Paik S Shak G Tang C Kim J Baker M Cronin FL Baehner MG Walker D Watson T Park W Hiller ER Fisher DL Wickerham J Bryant N Wolmark 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 27 2817 2826 10.1056/NEJMoa041588 15591335 10.1056/NEJMoa041588 1:CAS:528:DC%2BD2MXhslymsw%3D%3D (Pubitemid 40051905)
2. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8 (3):R25
3. FJ Esteva AA Sahin M Cristofanilli K Coombes SJ Lee J Baker M Cronin M Walker D Watson S Shak GN Hortobagyi 2005 Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy Clin Cancer Res 11 9 3315 3319 15867229 10.1158/1078-0432.CCR-04-1707 1:CAS:528:DC%2BD2MXjslOqtro%3D (Pubitemid 40627881)
4. L Gianni M Zambetti K Clark J Baker M Cronin J Wu G Mariani J Rodriguez M Carcangiu D Watson P Valagussa R Rouzier WF Symmans JS Ross GN Hortobagyi L Pusztai S Shak 2005 Original reports-Breast Cancer-gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer J Clin Oncol 23 29 7265 16145055 10.1200/JCO.2005.02.0818 1:CAS:528:DC%2BD2MXhtF2nsL3K (Pubitemid 46202341)
5. M Toi H Iwata T Yamanaka N Masuda S Ohno S Nakamura T Nakayama M Kashiwaba S Kamigaki K Kuroi 2010 Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population Cancer 116 13 3112 3118 10.1002/cncr.25206 20564629 10.1002/cncr.25206 1:CAS:528:DC%2BC3cXptlWqurg%3D
6. S Paik G Tang S Shak C Kim J Baker W Kim M Cronin FL Baehner D Watson J Bryant JP Costantino CE Geyer Jr DL Wickerham N Wolmark 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 23 3726 3734 10.1200/JCO.2005.04.7985 16720680 10.1200/JCO.2005.04.7985 1:CAS:528:DC%2BD28XpsVaqsrs%3D (Pubitemid 46622311)
7. RW Carlson DC Allred BO Anderson HJ Burstein WB Carter SB Edge JK Erban WB Farrar LJ Goldstein WJ Gradishar DF Hayes CA Hudis M Jahanzeb K Kiel BM Ljung PK Marcom IA Mayer B McCormick LM Nabell LJ Pierce EC Reed ML Smith G Somlo RL Theriault NS Topham JH Ward EP Winer AC Wolff 2009 Breast cancer Clinical practice guidelines in oncology J Natl Compr Cancer Netw 7 2 122 192 1:CAS:528:DC%2BD1MXjs1Oktbg%3D
8. L Harris H Fritsche R Mennel L Norton P Ravdin S Taube MR Somerfield DF Hayes RC Bast Jr 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 33 5287 5312 10.1200/JCO.2007.14.2364 17954709 10.1200/JCO.2007.14.2364 1:CAS:528:DC%2BD2sXhsVKnsbzK (Pubitemid 350232263)
9. MB Flanagan DJ Dabbs AM Brufsky S Beriwal R Bhargava 2008 Histopathologic variables predict Oncotype DX recurrence score Mod Pathol 21 10 1255 1261 10.1038/modpathol.2008.54 18360352 10.1038/modpathol.2008.54 1:CAS:528:DC%2BD1cXhtFGhs7fP
10. J Cuzick M Dowsett C Wale J Salter E Quinn L Zabaglo A Howell A Buzdar JF Forbes 2009 Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score-results from TransATAC Cancer Res 69 24 74 10.1158/0008-5472.SABCS-09-74
11. J Auerbach M Kim S Fineberg 2010 Can features evaluated in the routine pathologic assessment of lymph node-Negative Estrogen Receptor-positive stage I or II invasive breast cancer be used to predict the oncotype DX recurrence score? Arch Pathol Lab Med 134 11 1697 1701 10.1043/2009-0439-OAR.1 21043825
12. I Wolf N Ben-Baruch R Shapira-Frommer S Rizel H Goldberg N Yaal-Hahoshen B Klein DB Geffen B Kaufman 2008 Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study Cancer 112 4 731 736 10.1002/cncr.23225 18076012 10.1002/cncr.23225 (Pubitemid 351240566)
13. JM Harvey GM Clark CK Osborne DC Allred 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 5 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
14. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 1 18 43 19548375 1:CAS:528: DC%2BD2sXhsVOmu74%3D (Pubitemid 46174133)
15. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145 10.1200/JCO.2006.09.2775 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
16. AM Gown LC Goldstein TS Barry SJ Kussick PL Kandalaft PM Kim CC Tse 2008 High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system Mod Pathol 21 10 1271 1277 18487992 10.1038/modpathol.2008.83 1:CAS:528:DC%2BD1cXhtFGhs7bL
17. ALP Alkushi A Coldman D Huntsman D Miller CB Gilks 2004 Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level Int J Gynecol Pathol 23 2 129 137 15084841 10.1097/00004347-200404000-00007 (Pubitemid 38391772)
18. Breiman L (1984) Classification and regression trees. The Wadsworth statistics/probability series. Wadsworth International Group, Belmont, CA
19. CM Kelly S Krishnamurthy G Bianchini JK Litton AM Gonzalez-Angulo GN Hortobagyi L Pusztai 2010 Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers Cancer 116 22 5161 5167 10.1002/cncr.25269 20665886 10.1002/cncr.25269
20. K Gwin M Pinto FA Tavassoli 2009 Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score Int J Surg Pathol 17 4 303 310 10.1177/1066896909340274 19578051 10.1177/1066896909340274 1:CAS:528:DC%2BD1MXhtVeisLbE
21. J Geradts SM Bean RC Bentley WT Barry 2010 The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features Cancer Invest 28 9 969 977 10.3109/07357907.2010.512600 20873988 10.3109/07357907.2010.512600
22. M Stendahl L Ryden B Nordenskjold PE Jonsson G Landberg K Jirstrom 2006 High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients Clin Cancer Res 12 15 4614 4618 10.1158/1078-0432.CCR-06-0248 16899609 10.1158/1078-0432.CCR-06-0248 1:CAS:528:DC%2BD28XnvVGks70%3D (Pubitemid 44297812)
23. G Arpino H Weiss AV Lee R Schiff S De Placido CK Osborne RM Elledge 2005 Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance J Natl Cancer Inst 97 17 1254 1261 10.1093/jnci/dji249 16145046 10.1093/jnci/dji249 1:CAS:528:DC%2BD2MXpvFKjsrk%3D (Pubitemid 41535366)
24. S Liu SK Chia E Mehl S Leung A Rajput MC Cheang TO Nielsen 2009 Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients Breast Cancer Res Treat 119 1 53 61 10.1007/s10549-009-0318-0 19205877 10.1007/s10549-009- 0318-0
25. P Tang J Wang DG Hicks X Wang L Schiffhauer L McMahon Q Yang M Shayne A Huston KA Skinner J Griggs G Lyman 2010 A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer Cancer Invest 28 9 978 982 10.3109/07357907.2010.496754 20690804 10.3109/07357907.2010.496754
26. LJ Goldstein R Gray S Badve BH Childs C Yoshizawa S Rowley S Shak FL Baehner PM Ravdin NE Davidson GW Sledge Jr EA Perez LN Shulman S Martino JA Sparano 2008 Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features J Clin Oncol 26 25 4063 4071 10.1200/JCO.2007.14.4501 18678838 10.1200/JCO.2007.14.4501
27. FQC Baehner C Pomeroy C Cherbavaz S Shak 2009 Biopsy cavities in breast cancer specimens: their impact on quantitative RT-PCR gene expression profiles and recurrence risk assessment Mod Pathol 22 1s 4A 11A 10.1038/modpathol.2008. 208 10.1038/modpathol.2008.208